No Data
No Data
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 64%
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Express News | FibroGen Initiated Restructuring Plan Following Negative Pamrevlumab Trial Data; Plan Includes 75% U.S. Workforce Reduction Affecting 127 Employees
FibroGen to Incur $16M-$18M Restructuring Charge Amid Layoffs
Express News | FibroGen : Majority of Restructuring Charges Expected in Second Half of 2024
Express News | FibroGen Inc: Estimates Non-Recurring Charges of $16-18 Million for Restructuring
No Data